efgartigimod alfa   Click here for help

GtoPdb Ligand ID: 9777

Synonyms: ARGX-113 | efgartigimod alfa-fcab | Vyvgart®
Approved drug Immunopharmacology Ligand
efgartigimod alfa is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Efgartigimod alfa (ARGX-113) is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G (IgG) autoantibodies [6]. It binds to the IgG receptor, major histocompatibility complex class I-like Fc receptor (FcRn, the protein product of the FCGRT gene). Efgartigimod alfa inactivates FcRn's IgG binding ability (the FcRn-IgG interaction normally protects IgG from degradation) thus facilitating accelerated catabolism of native pathogenic autoantibodies [3,5]. The mechanism of this drug action is discussed more comprehensively in Roopenian and Akilesh (2007) [4] and Vaccaro et al. (2005) [7].
No information available.
Summary of Clinical Use Click here for help
The reference version of efgartigimod (efgartigimod alfa-fcab; ARGX-113) was advanced to clinical evaluations in patients with myasthenia gravis (MG), pemphigus vulgaris and primary immune thrombocytopenia. Click here to view ClinicalTrials.gov's registered ARGX-113 trials. ARGX-113 was granted FDA orphan drug designation for the treatment of MG in September 2017 [1]. In December 2021 the US FDA approved efgartigimod alfa-fcab (Vyvgart®) as a treatment for MG. EMA authorisation for Vyvgart® was issued in 2022.